Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 10/20 | 0.66 |
| ▸ | ADORA2A | P29274 | 8/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.50 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20041347 | 0.87 | ADORA1 (0.77) | ADORA1ADORA2AHSD17B10KMT2AMEN1 | |
| SCHEMBL31591781 | 0.87 | KMT2A (0.71) | ADORA1ADORA2AHSD17B10KMT2AMEN1 | |
| SCHEMBL23852855 | 0.87 | KMT2A (0.71) | ADORA1ADORA2AHSD17B10KMT2AMEN1 | |
| SCHEMBL32688280 | 0.86 | ADORA1 (0.58) | ADORA1ADORA2AHSD17B10KMT2AMEN1 | |
| SCHEMBL17131839 | 0.81 | ADORA1 (0.53) | ADORA1ADORA2AHSD17B10KMT2AMEN1 | |
| SCHEMBL4421556 | 0.80 | NPC1 (0.49) | ADORA1ADORA2AHSD17B10POLBALDH1A1 | |
| SCHEMBL19665238 | 0.80 | ADORA1 (0.69) | ADORA1ADORA2AHSD17B10ADORA2B | |
| SCHEMBL22115385 | 0.79 | ADORA1 (0.66) | ADORA1ADORA2AHSD17B10KMT2AMEN1 | |
| SCHEMBL19305511 | 0.79 | KMT2A (0.85) | ADORA1ADORA2AHSD17B10KMT2AMEN1 | |
| SCHEMBL19885521 | 0.78 | HPGD (0.74) | ADORA1ADORA2AHSD17B10KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220096450-A1 | Compounds and Methods for Treating or Preventing Heart Failure | DREXEL UNIVERSITY | 2022-03-31 | — | — | US | disclosed |
| WO-2020146636-A1 | COMPOUNDS AND METHODS FOR TREATING OR PREVENTING HEART FAILURE | DREXEL UNIVERSITY (US) | 2020-07-16 | — | — | WO | disclosed |
| WO-2020146636-A1 | COMPOUNDS AND METHODS FOR TREATING OR PREVENTING HEART FAILURE | DREXEL UNIVERSITY (US) | 2020-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220096450-A1 | Compounds and Methods for Treating or Preventing Heart Failure | SQOR, QSOX1, KEAP1 | ADORA1 1478/4885ADORA2A 2429/4885HSD17B10 562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.